A China-based venture capital investor manages seven USD funds with limited partners from prestigious academic institutions and hospital systems in the United States. The firm is capable of investing at any stage, from seed to pre-IPO. While the firm manages USD funds, it is rooted in China and is particularly interested in opportunities with a China angle or involving Asian founders.
The firm has previously invested at the intersection of AI and healthcare, such as AI-driven drug discovery, diagnostics, and imaging, but has broadened its scope to include therapeutics. The firm is particularly interested in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is open to various indications, prioritizing those with considerable market potential, such as oncology, immunology, CNS, pain management, and kidney diseases. In terms of development phases, the firm prefers companies from IND to clinical phases but is willing to consider companies in the PCC phase at the earliest.
The firm prefers companies with strong management teams, particularly those with industry experience in pharma or biotech.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment